Other studies have found that inhibiting NF-κB pathway via different ways alleviates liver fibrosis and this function is mainly achieved by suppressing HSC activation (Liu et al., 2020; Xia et al., 2020), implying that NF-κB inhibition leads to HSC quiescence, thereby preventing liver fibrosis development. The gene discussed is NFKB1; the disease is Hepatic fibrosis.